• Home
  •  / Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

OverviewSuggest Edit

Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines for the treatment of eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. Its products include injections to treat macular edema, moderate-to-severe atopic dermatitis, heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, rheumatoid arthritis. The company also offers injections to treat cryopyrin-associated periodic syndromes and metastatic colorectal cancer. In addition, it develops a trap-based clinical product for the treatment of neovascular glaucoma, and antibody-based clinical programs.

TypePublic
Founded1988
HQTarrytown, NY, USMap
Websiteregeneron.com
Employee Ratings3.9More
Overall CultureC+More
View Jobs (581)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2020)9,123(+13%)
Job Openings581
Revenue (FY, 2020)$8.5 B(+9%)
Share Price (Jul 2021)$583.2(-1%)

Key People/Management at Regeneron Pharmaceuticals

Leonard S. Schleifer

Leonard S. Schleifer

Founder, President and Chief Executive Officer
Dan van Plew

Dan van Plew

Executive Vice President and General Manager, Industrial Operations and Product Supply
George D. Yancopoulos

George D. Yancopoulos

Scientific Founder, President and Chief Scientific Officer
Nouhad Husseini

Nouhad Husseini

Senior Vice President, Business Development
Chris Fenimore

Chris Fenimore

Senior Vice President, Head of Accounting and Controller
Robert E. Landry

Robert E. Landry

Executive Vice President, Finance and Chief Financial Officer
Show more

Regeneron Pharmaceuticals Office Locations

Regeneron Pharmaceuticals has offices in Tarrytown, Bernards, Rensselaer, Sleepy Hollow and in 4 other locations
Tarrytown, NY, US (HQ)
777 Old Saw Mill River Rd
Bernards, NJ, US
110 Allen Rd, Basking Ridge
Rensselaer, NY, US
81 Columbia Turnpike
Sleepy Hollow, NY, US
1 Rockwood Rd
Washington, DC, US
1399 New York Ave NW
Dublin, IE
Harcourt St
Show all (8)

Regeneron Pharmaceuticals Financials and Metrics

Regeneron Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Regeneron Pharmaceuticals's revenue was reported to be $8.5 b in FY, 2020 which is a 8.1% increase from the previous period.
USD

Revenue (Q1, 2021)

2.5b

Gross profit (Q1, 2021)

2.2b

Gross profit margin (Q1, 2021), %

87.8%

Net income (Q1, 2021)

1.1b

EBIT (Q1, 2021)

1.1b

Market capitalization (16-Jul-2021)

62.1b

Closing stock price (16-Jul-2021)

583.2

Cash (31-Mar-2021)

1.4b

EV

63.4b
Regeneron Pharmaceuticals's current market capitalization is $62.1 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

6.7b7.9b8.5b

Revenue growth, %

14%17%8%

Cost of goods sold

434.1m782.2m1.1b

Gross profit

6.3b7.1b7.4b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.7b1.9b2.0b1.8b2.0b2.3b2.5b

Cost of goods sold

179.2m152.5m226.6m217.3m275.5m274.0m308.0m

Gross profit

1.5b1.8b1.8b1.6b1.7b2.0b2.2b

Gross profit Margin, %

90%92%89%88%86%88%88%
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

1.5b1.6b2.2b

Accounts Receivable

2.2b2.7b3.1b

Prepaid Expenses

243.3m387.1m160.8m

Inventories

1.2b1.4b1.9b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

1.7b1.0b1.4b2.2b2.0b1.6b1.4b

Accounts Receivable

2.3b2.5b2.7b2.9b2.8b4.0b4.2b

Prepaid Expenses

182.2m208.2m226.9m226.6m263.8m230.6m213.6m

Inventories

1.2b1.3b1.3b1.5b1.6b1.8b2.2b
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

2.4b2.1b3.5b

Depreciation and Amortization

148.2m210.3m235.9m

Inventories

(387.9m)(335.5m)(529.4m)

Accounts Payable

210.0m444.5m118.9m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

461.1m654.2m1.3b624.6m1.5b2.4b1.1b

Depreciation and Amortization

51.0m103.1m156.0m56.1m114.9m174.2m67.4m

Inventories

(58.6m)(168.2m)(227.2m)(70.8m)(233.4m)(402.4m)(252.8m)

Accounts Payable

(19.6m)110.3m119.9m(85.2m)20.9m80.8m(34.7m)
show all
USDFY, 2018

EV/EBIT

15.7 x

EV/CFO

18.1 x

EV/FCF

21.9 x

Revenue/Employee

906.9k

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.3 x

P/E Ratio

17.5
Show all financial metrics

Regeneron Pharmaceuticals Operating Metrics

FY, 2018FY, 2019FY, 2020

Patents (US)

182131

Product Candidates

212232

Products

777

Trademarks

121318
Show all operating metrics

Regeneron Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Loop Road Holdings LLC
Old Saw Mill Holdings LLC
OSMR Holdings
OSMR International
Regeneron Assurance, Inc.
Regeneron Atlantic Holdings
Regeneron Belgium BV
Regeneron Canada Company
Regeneron Capital International B.V.
Regeneron Genetics Center LLC
Show more

Regeneron Pharmaceuticals Revenue Breakdown

Embed Graph

Regeneron Pharmaceuticals revenue breakdown by business segment: 65.5% from Product Sales, 27.9% from Sanofi and Bayer Collaboration and 6.6% from Other

Human Capital Metrics

Source: craft.co
Embed Graph
Show all human capital metrics

Regeneron Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Regeneron Pharmaceuticals Online and Social Media Presence

Regeneron Pharmaceuticals's Trends

Embed Graph

Regeneron Pharmaceuticals Company Culture

  • Overall Culture

    C+

    73/100

  • CEO Rating

    C+

    72/100

  • Compensation

    C+

    74/100

Learn more on Comparably

Regeneron Pharmaceuticals News and Updates

April 20, 2021

Up 6% Last Week Can Regeneron Pharmaceuticals Stock Rise Further?

Over the past few months we have maintained our view that Regeneron stock looks undervalued. The stock has largely been in focus since last year amid the development of REGEN-COV, its Covid-19 antibody cocktail. While the treatment has already secured the U.S. FDA EUA (emergency use authorization)..
November 07, 2020

Regeneron Pharmaceuticals Earns Top Buy Rating For November

Just because a company has a good quarter in the past doesn’t mean that their stock prices will continue to rise in the future. That’s why our AI models provide an in-depth look at a company’s financials and performance so you can make the best decisions for your portfolio.
September 05, 2020

Kaskela Law LLC Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Long-Term REGN Stockholders to Contact the Firm

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of the Company's stockholders. On June 24, 2020, the U.S. Attorney's Office filed a complaint against...
August 20, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals Inc.

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). The investigation concerns whether Regeneron and certain of its officers and/or directors have breached...
July 23, 2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc.

NEW YORK, July 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). If you are a Regeneron shareholder and wish to...
July 03, 2020

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Longtime Shareholders in Regeneron Pharmaceuticals (REGN) to Contact its Attorneys: Firm Investigating Possible Breach of Fiduciary Duties

SAN FRANCISCO, July 2, 2020 /PRNewswire/ -- Hagens Berman urges longtime shareholders in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to submit their losses now. The firm is investigating whether Regeneron's directors breached their fiduciary duties. Relevant Holding Period: At least...
Show more

Regeneron Pharmaceuticals Blogs

July 07, 2021

Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021

TARRYTOWN, N.Y. , July 7, 2021 /PRNewswire/ --  Regeneron Pharmaceuticals, Inc. (NASDAQ:   REGN) today announced that it will report its second quarter 2021 financial and operating results on Thursday, August 5, 2021 , before the U.S. financial markets open.
July 01, 2021

Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity

Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity Content Import Thu, 07/01/2021 - 14:05 Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity July 1, 2021 at 2:05 PM EDT This release is a bac…
June 22, 2021

Regeneron to Participate in Guggenheim Biopharma Strategy Series

TARRYTOWN, N.Y. , June 22, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:   REGN) is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – at 10:00 a.m.
May 21, 2021

Teen Scientists and Engineers Win $5 Million at Largest Global High School STEM Competition

Teen Scientists and Engineers Win $5 Million at Largest Global High School STEM Competition Content Import Fri, 05/21/2021 - 11:45 Teen Scientists and Engineers Win $5 Million at Largest Global High School STEM Competition May 21, 2021 at 11:45 AM EDT This rel…
May 19, 2021

Libtayo® (cemiplimab-rwlc) Presentations at ASCO Highlight Expanding Clinical Data in Diverse Cancers

TARRYTOWN, N.Y. , May 19, 2021 /PRNewswire/ --  Presentations include first positive clinical data for the fianlimab (LAG-3 inhibitor) and Libtayo combination in advanced melanoma Regeneron will host an investor webcast on Monday, June 7 to provide further updates across its oncology portfolio
May 17, 2021

Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients

TARRYTOWN, N.Y. , May 17, 2021 /PRNewswire/ --  Patients treated with REGEN-COV had 4-day shorter duration of symptoms and significantly reduced viral load compared to placebo Similar efficacy observed with both doses (1,200 mg and 2,400 mg); U.S. FDA is currently reviewing request to add lower
Show more

 Regeneron Pharmaceuticals Frequently Asked Questions

  • When was Regeneron Pharmaceuticals founded?

    Regeneron Pharmaceuticals was founded in 1988.

  • Who are Regeneron Pharmaceuticals key executives?

    Regeneron Pharmaceuticals's key executives are Leonard S. Schleifer, Dan van Plew and George D. Yancopoulos.

  • How many employees does Regeneron Pharmaceuticals have?

    Regeneron Pharmaceuticals has 9,123 employees.

  • What is Regeneron Pharmaceuticals revenue?

    Latest Regeneron Pharmaceuticals annual revenue is $8.5 b.

  • What is Regeneron Pharmaceuticals revenue per employee?

    Latest Regeneron Pharmaceuticals revenue per employee is $931.4 k.

  • Who are Regeneron Pharmaceuticals competitors?

    Competitors of Regeneron Pharmaceuticals include Catalent, Bristol-Myers Squibb and Idorsia.

  • Where is Regeneron Pharmaceuticals headquarters?

    Regeneron Pharmaceuticals headquarters is located at 777 Old Saw Mill River Rd, Tarrytown.

  • Where are Regeneron Pharmaceuticals offices?

    Regeneron Pharmaceuticals has offices in Tarrytown, Bernards, Rensselaer, Sleepy Hollow and in 4 other locations.

  • How many offices does Regeneron Pharmaceuticals have?

    Regeneron Pharmaceuticals has 8 offices.